Q: Approximately 10% of pediatric patients with acute lymphoblastic leukemia (ALL) are not cured by current therapy because of the development of drug resistance. What are some of the known mechanisms of drug resistance, and what are the emerging therapeutics to mitigate resistance? A: The...
Q: What is it to be overwhelmed by the need to act? A: It only takes one experience of a loved one's diagnosis of advanced cancer to be jarred, because quite frankly, navigating a cancer diagnosis is a nightmare. ...
Clinical genomics is often considered to be risky for commercial labs to spin up because of concerns around profitability. Two commonly invoked reasons for this are under resourced billing and authorization services at medical centers and poor reimbursement of the tests. ...
Q: Why do you believe patients need to take control of their health data? A: I’ll give an example. In the last year of her life as a Stage IV Metastatic Breast Cancer patient, my little sister Tania visited 17 facilities around the US and was...
Q: What were the key investment criteria that led you to invest in the clinical diagnostics startups in your portfolio? A: We look for companies that can help improve the quality of care that is delivered while ideally creating a better individual experience and driving...
Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? A: We...
Q: What are some of the biggest challenges we need to overcome to drive the adoption of clinical genomics and realize the benefits of truly personalized medicine? What promises for improved outcomes for a patient can we expect in a more technologically advanced personalized health...
Q: What are some of the biggest challenges we need to overcome to make the use of clinical genomics a successful implementation for each of the stakeholders? A: There are multiple challenges that remain. The estimated cost to develop a diagnostic not linked to a medicine...
Q: You joined Adaptive Biotechnologies in April as Chief Medical Officer, overseeing translational research and clinical development to help support product development from the immune medicine platform. What are you most excited about? A: One of the things that excited me most about joining Adaptive Biotechnologies...
Q: One of the major barriers to implementing pharmacogenetic results into routine clinical care had been the lack of clinical guidance on how to use genetic test results to adjust the use or dose of medications. What has the Clinical Pharmacogenetics Implementation Consortium (CPIC) been...
